Investment Rating - The industry rating is "Outperform the Market" [6] Core Views - The report highlights that CATL is set to list on the Hong Kong Stock Exchange, with 90% of the raised funds directed towards projects in Hungary [9] - The CIBF2025 event concluded successfully, showcasing advancements in solid-state battery technology [10] - April saw record high wholesale volumes for passenger vehicles, with significant growth in exports of new energy passenger vehicles [11][12] Summary by Sections New Energy Vehicles and Lithium Battery Sector - CATL's upcoming Hong Kong listing aims to enhance local supply capabilities through significant investment in Hungary [9] - The CIBF2025 event featured the launch of new battery technologies, including a third-generation battery with energy density exceeding 500Wh/kg [10] - April's wholesale volume for passenger vehicles reached 2.19 million units, marking a year-on-year increase of 10.7% and a penetration rate of over 50% for new energy vehicles [11] Photovoltaic Sector - The silicon material segment is undergoing a "production reduction to support prices" strategy, with a decrease in production across the industry [19] - Major silicon manufacturers are reportedly planning to consolidate remaining production capacities, which could positively impact market expectations [21][22] - The report notes a slight decline in silicon wafer prices and a stable market for solar glass, with some companies adjusting their production schedules [23][24] Energy Storage Sector - The report discusses a surge in energy storage demand in South Asia due to geopolitical tensions, particularly between India and Pakistan [32] - Shanghai is exploring a capacity compensation mechanism to encourage independent energy storage projects [36] - The demand for energy storage is expected to grow significantly, with various initiatives being launched to support this sector [35] Power Equipment and Industrial Control Sector - The Xinjiang to Sichuan ultra-high voltage project is expected to commence construction in December 2025, enhancing power transmission capabilities [42][44] - The State Grid has released a white paper on "Artificial Intelligence + Power," indicating ongoing digital transformation in the industry [45] - The manufacturing PMI has slightly declined, but new automation technologies are being introduced to improve efficiency [46] Hydrogen Energy Sector - Various regions are implementing supportive policies for hydrogen energy production, including fee exemptions for hydrogen fuel cell vehicles [53][55] - Technological breakthroughs in flexible hydrogen liquefaction systems and offshore wind power hydrogen storage systems have been achieved [56] - The report suggests a growing focus on green hydrogen and fuel cell technologies, with several companies positioned to benefit from these trends [57]

轻工制造 GLO 日本试销推进，新型烟草趋势向上 投资要点： 【周观点】5 月 12 日日本 GLO 官网公布新品 HILO 信息，新品预期将于 6 月 9 日在日本宫城县试销限定发售，若日本市场试销良好，产品力进一 步验证，思摩尔 HNB 业务成长空间有望进一步打开；本周中美贸易冲突暂 缓，优质低估出口链、以及前期受外销业务担忧的包装龙头迎来布局窗口； 出口情绪好转带动包装纸企涨价潮，玖龙、山鹰、理文等集体发布提价函。 强于大市（维持评级） 一年内行业相对大盘走势 -0.30 -0.20 -0.10 0.00 0.10 0.20 5/20 7/31 10/11 12/22 3/4 5/15 轻工制造 沪深300 团队成员 | 分析师： | 李宏鹏(S0210524050017) | | --- | --- | | lhp30568@hfzq.com.cn | | | 分析师： | 汪浚哲(S0210524050024) | | wjz30579@hfzq.com.cn | | | 分析师： | 李含稚(S0210524060005) | | lhz30597@hfzq.com.cn | | 华福证券 轻工制 ...

Group 1 - The report emphasizes that the recent public fund regulations are a necessary result of long-term changes in China's capital market structure and economic structure [3] - The market style is shifting from low-volatility strategies to core assets, indicating a potential long-term decline in China's capital intensity [3][24] - In the short to medium term, the core asset style needs to recover, while in the long term, it reflects the cyclical bottoming of the economy [3][24] Group 2 - The report notes that the resilience of the US economy is weakening, with inflation structures continuing to adjust; April's CPI inflation year-on-year was 2.3%, while core CPI remained at 2.8% [8][11] - The US PPI inflation showed a month-on-month decline of -0.47% in April, with service PPI contributing significantly to this decline [9][12] - Retail sales in the US also showed weak growth, with a month-on-month increase of only 0.058% in April, indicating a drag on consumption [11][12] Group 3 - The report highlights the mutual reduction of trade barriers between China and the US, with both countries agreeing to cancel 91% of tariffs and establish a mechanism for ongoing economic negotiations [13][15] - The Hong Kong stock market saw a general increase, with the Hang Seng Index rising by 2.09% [16] - The report indicates a lack of clear main lines in the Hong Kong market, with sectors like security, NFT concepts, and building energy efficiency leading the gains [19][24] Group 4 - The report suggests that the growth style may continue to adjust due to a lack of event catalysts [3][24] - In terms of industry performance, financial and real estate sectors led the gains, while technology sectors faced declines [32][24] - The report also notes a divergence in foreign capital index futures holdings, with net short positions expanding in some indices [44]

分析师： 周浦寒(S0210524040007) zph30515@hfzq.com.cn 研究助理： 杨逸帆(S0210124110046) yyf30689@hfzq.com.cn 策 略 研 究 华福证券 29 只医药生物主题走出见底形态 团队成员 投资要点： 策 略 定 期 报 告 主题投资数据库旨在筛选优秀量价形态的主题机会，把握热门主题的 见顶节奏、龙头股的调整程度。在 3/9 发布的《主题投资的下半场决胜法 则》中，我们构建了主题投资的数据追踪体系。我们专注于 2 方面：1）4 种形态量化筛选，高赔率的主题机会；2）构建交易热度指标，把握热门主 题的见顶节奏，并最新增加了龙头股的调整程度观察。后续，我们将定期 更新主题投资数据体系。我们希望通过这种偏量化的方式，给予投资者更 客观的参考，把握住主题投资的行情节奏。 29 只医药生物主题走出见底形态。本期走出见底、突破、主升、加速 的主题指数数量分别有 79、38、9、0 只。其中，79 只见底形态的主题指 数多为医药生物行业（29 只）；而 38 只突破形态的主题指数中，行业多 为国防军工（7 只）、通信（5 只）和有色金属（5 只）。9 只主升 ...

Investment Rating - The industry rating is "Outperform the Market," indicating that the overall return of the industry is expected to exceed the market benchmark index by more than 5% in the next 6 to 12 months [56]. Core Insights - The Wind New Materials Index closed at 3636.37 points, reflecting a week-on-week increase of 0.57%. Among the six sub-industries, the semiconductor materials index decreased by 1.1%, while the carbon fiber index increased by 3.51% [3][11]. - Jilin Chemical Fiber announced a price increase of 10,000 yuan per ton for its wet-process 3K carbon fiber products, driven by rising demand from the low-altitude economy and drones, leading to a supply shortage [4][34]. - The U.S. Department of Commerce announced the withdrawal of the "AI Diffusion Rule" and plans to globally ban the use of Huawei AI chips, which may impact the semiconductor industry [4][34][36]. Market Overview - The semiconductor materials index reported a decrease to 6016.16 points, while the organic silicon materials index rose to 6017.89 points, reflecting a 2.75% increase. The carbon fiber index reached 1258.11 points, up 3.51% [3][11]. - The top five gainers in the week included companies like Stik (10.77%) and Kaisheng Technology (7.81%), while the top five losers included Huate Gas (-6.9%) and Aladdin (-6.88%) [25][27]. Recent Industry Trends - The recent U.S.-China trade talks resulted in the cancellation of 91% of tariffs imposed by the U.S. on Chinese goods, which is expected to positively influence bilateral trade relations [29][31]. - BYD is making significant moves into the electric two-wheeler market, indicating a growing trend in electric vehicle adoption [34]. Key Companies to Watch - The report highlights several companies with strong growth potential, including Tongcheng New Materials in the photoresist sector, Huate Gas in specialty gases, and Guocera Materials in the new materials sector [4][34].

行 华福证券 纺织服饰 2025 年 05 月 18 日 业 研 究 行 业 纺织服饰 户外专题（二）：从专业到破圈，解析伯希和高 投资要点： 户外专题（二）：从专业到破圈，解析伯希和高性能户外增长密码 定 期 报 告 伯希和以"科技堆料"构建差异化优势，依托 PT-China 平台自主 研发 STORM BREATH 防水透湿等核心技术，并引入全球顶尖供应链 资源，形成"自主+外采"双轨技术体系。产品矩阵覆盖四大梯度系列 （巅峰、专业性能、山系列、经典系列），2024 年 SPU 达 572 个。渠 道策略上，线上 DTC 为核心（2024 年营收占比 77%），线下 DTC 通 过联营模式快速扩张，三年收入 CAGR 达 383%，一二线城市门店占 比提升至 62%，实现高效市场渗透。 行情数据 本周家电板块涨跌幅+0.3%，其中白电/黑电/小家电/厨电板块涨跌 幅分别+0.4%/-2.9%/+1.0%/+0.6%。原材料价格方面，LME 铜、LME 铝环比上周分别+1.32%、+4.95%。 本周纺织服装板块涨跌幅+1.01%，其中纺织制造涨跌幅+0.94%， 服装家纺涨跌幅+0.60%。本周 328 ...

Investment Rating - The report maintains an "Outperform" rating for the defense and military industry [4]. Core Insights - The core viewpoint emphasizes that domestic trade and military trade continue to drive demand in the industry [10][48]. Summary by Sections Industry Overview - The "New Era of China's National Security" white paper was released on May 12, outlining China's strategic focus on national security and its interaction with global stability [48]. - Recent defense sales agreements were made with Saudi Arabia, Qatar, and the UAE, totaling approximately $4.3 billion, indicating strong international demand for military equipment [49][50][51]. Market Performance - The military industry index (801740) decreased by 1.18% from May 12 to May 16, underperforming compared to the Shanghai and Shenzhen 300 index, which increased by 1.12% [19]. - The military index has increased by 0.68% since 2025, while the Shanghai and Shenzhen 300 index has decreased by 1.16%, showing relative strength in the long term [21]. Investment Opportunities - The report identifies three main investment lines: domestic trade, foreign trade, and self-sufficiency [54]. - Domestic Trade: Companies such as Tianqin Equipment, Gaode Infrared, and others are highlighted [54]. - Foreign Trade: Companies like Guangdong Hongda and Aerospace Rainbow are recommended [55]. - Self-Sufficiency: Companies involved in commercial engines and nuclear fusion are noted [56]. Financial Insights - As of May 16, the military industry index has a TTM price-to-earnings ratio of 65.05, indicating a high valuation but potential for recovery in demand by 2025 [53][38]. - Passive fund inflows into military ETFs have increased, suggesting a positive outlook for the sector [32].

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical industry [6]. Core Insights - The report emphasizes the significant progress in stem cell therapy across multiple indications, suggesting a focus on companies like Jiuzhitang and Zhongyuan Qihe [3][5]. - The investment strategy is centered around three main themes: innovation, recovery, and policy support, with a strong emphasis on innovative drugs as the most clear long-term trend in the pharmaceutical sector [5]. Summary by Sections 1. Investment Focus on Pharmaceutical Combinations - The recommended investment combination outperformed the pharmaceutical index by 2.8 percentage points and the broader market by 3.1 percentage points last week [12]. 2. Stem Cell Therapy: Policy and Progress - China's regenerative medicine has reached a world-leading level, with clear industry policies marking a golden development period for stem cell therapy [17]. - Multiple indications are seeing critical advancements, with expectations for key data releases this year [17]. - The first domestically approved stem cell therapy was launched in January 2025, marking a historic turning point for the industry [6][17]. 3. Weekly Market Review and Hotspot Tracking (May 12-16, 2025) - The CITIC Pharmaceutical Index rose by 1.4%, outperforming the CSI 300 Index by 0.3 percentage points, ranking 10th among CITIC's primary industry classifications [61]. - The pharmaceutical sub-sectors showed positive performance, with chemical raw materials up by 2.79% and traditional Chinese medicine up by 2.01% [64].

Investment Rating - The industry rating is "Outperform the Market" [7] Core Insights - Huawei's nova 14 series and Harmony OS computer product launch event is scheduled for May 19, 2025, marking it as one of the most significant events for Huawei in 2025 [3] - Apple's first foldable iPhone is expected to be released in the fall of 2026, alongside the iPhone 18 Pro series, with a projected global shipment of 3.8 million foldable smartphones in Q4 2024, a year-on-year decline of 18% [4] - Huawei holds a 31.2% market share in the foldable smartphone segment, while Samsung's market share has decreased to 26.7% [4] Summary by Sections Product Launches - Huawei's upcoming launch includes the nova 14 series and a new Harmony OS computer, potentially the first foldable PC from Huawei [3] Market Trends - The foldable smartphone market is experiencing a decline, with a significant drop in shipments, but Apple's entry is expected to revitalize the market due to its strong brand and integration capabilities [4] Investment Opportunities - Suggested areas for investment include 3D printing applications (e.g., Huazhu High-Tech, Plittech), automated assembly equipment (e.g., Bozhong Precision, Kuaike Intelligent), and automated testing equipment (e.g., Oatmeal Technology, Jepter) [5]

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected relative price increase of over 20% compared to the market benchmark within the next six months [5][22]. Core Insights - The company has demonstrated impressive performance with a revenue of 3.56 billion yuan in 2024, reflecting a year-on-year growth of 76.3%, and a net profit of 1.43 billion yuan, up 122% year-on-year [2][5]. - The sales expense ratio has improved, decreasing by 5.9 percentage points to 39.7% in 2024, while the net profit margin increased by 8.27 percentage points to 40.2% [2][3]. - The innovative pipeline is progressing steadily, with multiple clinical trials for the drug Vomeletin ongoing, targeting various indications [4][5]. Financial Performance - In Q4 2024, the company achieved a revenue of 1.02 billion yuan, a 52.8% increase year-on-year, and a net profit of 370 million yuan, up 57% year-on-year [2]. - For Q1 2025, the company reported a revenue of 1.1 billion yuan, a 47.9% increase year-on-year, and a net profit of 410 million yuan, reflecting a 34.1% growth [3]. - The projected net profits for 2025, 2026, and 2027 are estimated at 1.7 billion yuan, 2.03 billion yuan, and 2.49 billion yuan, respectively, indicating a strong growth trajectory [5]. Cost Management - The company has effectively optimized its cost structure, with a decrease in the management expense ratio to 4.6% in 2024, down 1.9 percentage points year-on-year [2]. - The research and development expense ratio also saw a decline to 8.8%, down 6.7 percentage points year-on-year, indicating efficient allocation of resources [2]. Market Position and Growth Potential - The company is in a rapid growth phase with Vomeletin's market expansion and the introduction of new products, highlighting its long-term growth potential [5]. - The introduction of the KRASG12C inhibitor, Goretinib, is expected to enhance the company's product offerings and market presence [4][5].